QS Investors LLC reduced its stake in shares of Bioverativ Inc (NASDAQ:BIVV) by 3.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,997 shares of the biotechnology company’s stock after selling 767 shares during the quarter. QS Investors LLC’s holdings in Bioverativ were worth $1,078,000 at the end of the most recent quarter.
Other large investors also recently added to or reduced their stakes in the company. TrueNorth Inc. acquired a new position in Bioverativ during the 4th quarter valued at $647,000. Bank of New York Mellon Corp raised its stake in Bioverativ by 11.1% during the 4th quarter. Bank of New York Mellon Corp now owns 1,382,422 shares of the biotechnology company’s stock valued at $74,541,000 after purchasing an additional 137,792 shares during the last quarter. Stifel Financial Corp acquired a new position in Bioverativ during the 3rd quarter valued at $3,576,000. ValueAct Holdings L.P. acquired a new position in Bioverativ during the 3rd quarter valued at $72,514,000. Finally, Wells Fargo & Company MN acquired a new position in Bioverativ during the 3rd quarter valued at $124,500,000. Hedge funds and other institutional investors own 97.18% of the company’s stock.
Shares of Bioverativ Inc (BIVV) opened at $104.98 on Friday. The stock has a market cap of $11,360.00 and a price-to-earnings ratio of 38.31. Bioverativ Inc has a fifty-two week low of $48.14 and a fifty-two week high of $105.01.
Bioverativ (NASDAQ:BIVV) last announced its quarterly earnings results on Tuesday, February 13th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.75 by $0.01. The firm had revenue of $328.70 million for the quarter, compared to analyst estimates of $325.89 million. Bioverativ had a net margin of 30.43% and a return on equity of 40.99%. equities analysts anticipate that Bioverativ Inc will post 3.82 earnings per share for the current year.
BIVV has been the subject of several research analyst reports. Zacks Investment Research upgraded shares of Bioverativ from a “hold” rating to a “buy” rating and set a $62.00 target price for the company in a research note on Monday, January 8th. Jefferies Group boosted their price target on shares of Bioverativ to $79.00 and gave the company a “buy” rating in a report on Thursday, January 18th. Raymond James Financial lowered shares of Bioverativ from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 23rd. Morgan Stanley raised shares of Bioverativ from an “underweight” rating to an “equal weight” rating in a report on Tuesday, January 23rd. Finally, Credit Suisse Group reissued a “neutral” rating and issued a $65.00 price target on shares of Bioverativ in a report on Thursday, January 18th. Twelve equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $63.83.
TRADEMARK VIOLATION WARNING: “Bioverativ Inc (BIVV) Shares Sold by QS Investors LLC” was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://ledgergazette.com/2018/03/23/bioverativ-inc-bivv-shares-sold-by-qs-investors-llc.html.
Bioverativ Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.